Table 1:

Brain MR imaging abnormalities, their distribution, locations of reduced diffusion, size of the largest WM lesion, %ADCR values, and clinical outcomes

No.Age (yr)SexSize (cm)Underlying DxEtiologiesGroupsRegions of Red. DiffusionFLAIR SeverityDWI Severity%ADC Red.Outcome
116M4.2 × 2.2ALLMethotrexateCFr, CS/CR110.321
214M2.1 × 0.8ALLMethotrexateCFr, CS/CR110.160
318M4.5 × 2.6ALLMethotrexateCFr+P, CS/CR120.392
416F2.1 × 1.8ALLCytarabineCFr, CS/CR110.352
511M4.5 × 2.2ALLMethotrexateCFr, CS/CR, CC020.362
611F4.1 × 1.8ALLMethotrexateCFr+P, CS/CR120.412
714FDAMLFludarabineCD, CS/CR, CC, Th440.323
817F2.3 × 0.4ALLMethotrexateCFr+P, CS/CR220.323
91F3.8 × 1.1ATRTCarboplatinCFr+P, CS/CR, Th230.574
1015F2.4 × 1.4PTLDMethotrexateCFr+P, CS/CR, BS, CC330.294
1110MDAMLFludarabineCD, CS/CR, Th, BS440.624
1217F5.4 × 2.0AMLFludarabineCFr+P, CS/CR220.484
1313F1.5 × 0.7JMMLBMTIFr, CS/CR110.170
1416F2.8 × 0.8AABMTIFr, CS/CR110.420
1517M1.3 × 1.1AMLCyclosporineIP, CS/CR110.061
1617F0AMLBMTINA100.020
171M2.8 × 0.5RMSBMTIFr, CS/CR110.152
187M3.9 × 1.9ATRTBevacizumabOFr, CS/CR110.512
1916M7.9 × 2.4ESRDUremiaOFr+P, CS/CR220.573
  • Note:—AA indicates aplastic anemia; ALL, acute lymphocytic leukemia; AML, acute myeloid leukemia; ATRT, atypical teratoid/rhabdoid tumor; %ADC red., percentage ADC reduction; BS, brain stem; CC, corpus callosum; CR, corona radiata; CS, centrum semiovale; D, diffuse; Dx, diagnosis; ESRD, end-stage renal disease; Fr, frontal; JMML, juvenile myelomonocytic leukemia; NA, not applicable; P, parietal; PTLD, post-transplant lymphoproliferative disorder; RMS, rhabdomyosarcoma; Th, thalami.